NeuroRx to host Expert Presentation on Role of NMDA in Depression and Suicidality at
Solebury Trout KOL day on November 15, 2019

Investors

NeuroRx is currently raising funds to support its ongoing clinical development of NRX-100/NRX-101  for the treatment of Bipolar Depression in patients with Acute Suicidal Ideation/Behavior (ASIB). If you are interested in learning more about NeuroRx and opportunities to invest in the company, please contact:


Investor Relations:

 

Solebury Trout

 

Chiara Russo - Vice President:

 

crusso@troutgroup.com

 

+1 617 221 9197 Direct

+1 617 306 9137 Cell

+1 646 378 2901 Fax

 

75 Arlington Street, Suite 5014

Boston, MA 02116

 

Brian Korb - Managing Director:

 

bkorb@troutgroup.com

 

+1 646 378 2923 Direct

+1 917 653 5122 Cell

+1 646 378 2901 Fax

 

740 Broadway, 9th Floor

New York, NY 10003

NRX-100/NRX/101 is the first sequential therapy to include an oral therapeutic in development for the treatment of Bipolar Depression in patients with Acute Suicidal Ideation/Behavior (ASIB)

Submitting Form...

The server encountered an error.

Form received.

Contact the NeuroRx Investor-Relations Team

© 2016 NeuroRx, Inc.

*These drugs are investigational and not approved by the US FDA

STAY CONNECTED